Roche secures rights to South Korean experimental obesity treatment

Roche has committed up to $2.3 billion to an obesity drug that is still in its first human trials. Through its California based subsidiary Genentech, the Basel headquartered pharmaceutical group has obtained worldwide rights, excluding South Korea, to Hanmi Pharmaceutical’s experimental treatment HM17321.

The agreement gives Genentech responsibility for development, manufacturing and commercialisation outside the South Korean market. Hanmi will receive an initial $190 million, while the remaining value depends on clinical results, regulatory approvals and eventual commercial performance.

The deal announced on August 24, 2026, gives Roche a foothold in one of the pharmaceutical industry’s most competitive fields. Demand for effective obesity medicines has driven major investment in treatments that can deliver sustained weight loss and address the health complications associated with obesity.

The agreement also shows how Roche is using partnerships to build its pipeline. HM17321 originated at Hanmi, a South Korean drugmaker, while Genentech brings the resources and international infrastructure needed for later stage trials and potential global distribution. South Korea remains outside Roche’s rights under the agreement.

HM17321 has not yet reached the stage where its effectiveness can be judged. Hanmi is currently conducting a Phase I trial, the early development stage that assesses safety and how the treatment behaves in the human body. Hanmi must complete that study before Genentech takes over for Phase II and subsequent trials.

That timetable leaves several scientific and commercial hurdles ahead. Phase II research will need to establish whether HM17321 produces meaningful weight loss and to define an appropriate dose. Later studies will have to test the treatment in larger patient populations and generate the evidence regulators require.

The candidate’s proposed distinction lies in its mechanism of action. Hanmi says it differs from GLP-1 type products, the class that has reshaped the obesity market. The treatment is expected to promote weight loss while preserving muscle mass, although the source material provides no clinical results confirming that effect.

For Roche, the agreement therefore represents a development bet rather than an immediate product launch. The company will need to decide how aggressively to invest as data emerge from Hanmi’s trial and future studies.

The agreement places Roche alongside companies competing to define the next generation of obesity treatments. GLP-1 medicines have established a powerful market model, but drugmakers are pursuing alternatives that could improve tolerability, dosing, durability or the quality of weight loss.

HM17321’s muscle preservation claim addresses one of the key issues in obesity drug development. Weight reduction can involve changes in body composition, and pharmaceutical companies are studying ways to target fat loss while retaining lean mass. The available information does not disclose trial results, patient numbers or the size of any observed effect for HM17321.

Those gaps matter because Roche’s potential payout is tied to evidence. Of the agreement’s $2.3 billion headline value, only $190 million is identified as an upfront payment. The balance will depend on milestones that have yet to be achieved.

The deal also reflects the increasingly international nature of pharmaceutical research. A South Korean company developed the candidate, a Swiss group obtained global rights outside Korea, and its US subsidiary will lead the later development work. Commercial success will depend on data, regulators and the ability to compete in a crowded global market.

For Switzerland, the agreement adds another externally sourced asset to Roche’s long term innovation strategy. The company will gain access to HM17321 through Genentech, linking Roche’s Basel base with research and development operations in the United States and Hanmi’s platform in South Korea.

The immediate Swiss impact is financial and strategic rather than clinical. HM17321 is not an approved medicine, and the source does not provide a launch timetable, projected pricing or information about manufacturing locations. Patients in Switzerland would only benefit if the candidate clears its trials, wins regulatory approval and reaches the market.

The next public milestones should come from Hanmi’s Phase I programme. Its completion will determine when Genentech can begin Phase II work. Results from those studies will show whether the drug’s proposed muscle preservation profile translates into a measurable benefit for patients.

Roche has secured an option on a promising concept, with the largest payments still conditional. The agreement gives the Swiss company time to assess the science while keeping development responsibility aligned with the stage of the evidence.